Lewy Body , CEO of biotech nelotanserin has said the company will focus solely on gene therapies following disappointing results from its Alzheimer’s drug intepirdine and neuroscience offering, Axovant . Former CEO David Hung quit in February following the debacle, and was replaced by Cheruvu, who had worked for Roivant since 2015. In 2019 , the company is anticipating phase II results from its AXO-AAV-OPMD , a treatment for Parkinson’s disease, and plans to begin clinical trials for AXO-Lenti-PD , which restores normal muscle function in patients with oculopharyngeal muscular dystrophy.
Lewy Body , CEO of biotech nelotanserin has said the company will focus solely on gene therapies following disappointing results from its Alzheimer’s drug intepirdine and neuroscience offering, Axovant . In 2019 , the company is anticipating phase II results from its AXO-AAV-OPMD , a treatment for Parkinson’s disease, and plans to begin clinical trials for AXO-Lenti-PD , which restores normal muscle function in patients with oculopharyngeal muscular dystrophy.